The deal is set to help Vertex’s development of next-generation gene editing therapies for sickle cell disease and ...

It's not fully appreciated how much of an impact sickle cell disease can have on a person's mental health, writes columnist.

and hemoglobinopathies, including sickle cell disease and glucose-6-phosphate dehydrogenase deficiency. Lastly, a practical approach to the diagnosis of chronic anemia is presented. Anemia is ...

ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRSP), a biopharmaceutical company focused on ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

CTX-131 is under clinical development by CRISPR Therapeutics and currently in Phase II for T-Cell Lymphomas. According to GlobalData, Phase II drugs for T-Cell Lymphomas have a 29% phase transition ...

Vertex aims to further bolster its gene-editing therapy pipeline by using Orna's lipid nanoparticle delivery technologies during the three-year collaboration.

These five geonomics and synthetic biology stocks are likely to soar in the short-term. They Are: CRSP, IMCR, GLUE, RIGL, CSTL.

13 In this way, it may resemble the hemoglobinopathies such as sickle-cell disease and hemoglobin C, which are also known to have relatively limited geographic distribution. The retrospective ...

More than 500,000 babies were tested for sickle cell disease in Catalonia’s newborn screening program, with 160 cases ...